Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 1
1995 1
1996 1
1999 1
2000 3
2004 1
2005 1
2006 1
2008 1
2010 2
2011 1
2012 2
2013 1
2014 4
2015 9
2016 8
2017 10
2018 25
2019 21
2020 3
2022 0
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 32366442

87 results
Results by year
Filters applied: . Clear all
Page 1
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
Markóczy Z, Sárosi V, Kudaba I, Gálffy G, Turay ÜY, Demirkazik A, Purkalne G, Somfay A, Pápai-Székely Z, Rásó E, Ostoros G. Markóczy Z, et al. BMC Cancer. 2018 May 25;18(1):598. doi: 10.1186/s12885-018-4283-z. BMC Cancer. 2018. PMID: 29801465 Free PMC article. Clinical Trial.
87 results